NTRK1 and neoplasm: Studies focused on targeted molecular therapies, such as receptor tyrosine kinase inhibitors and epigenetic modulators, the tumor microenvironment, and personalized medicine are gradually improving or replacing current aggressive treatments, such as chemotherapy and actinotherapy.